Defining signaling pathways and effective combination therapy to improve outcomes for patients with FGFR2-driven biliary cancer
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2210345
- Recipient
-
The Broad Institute, Inc. UEI H5G9NWEFHXN4
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $936,000
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Cambridge, MA 02142, USA
Award details come from USAspending.gov.
About this award
The Broad Institute, Inc. was awarded a $936,000 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The four-year award will fund research to define signaling pathways and effective combination therapies to improve outcomes for patients with FGFR2-driven biliary cancer. Through support of basic, applied, and advanced biomedical research, the Military Medical Research and Development program aims to transform health care for service members and the public by investigating medical solutions for the battlefield and beyond. This award will support The Broad Institute's work developing precision medicine approaches with the goal of improving prognosis for those suffering from this rare but deadly form of cancer.
Quick answers
Who received award W81XWH2210345?
W81XWH2210345 was awarded to The Broad Institute, Inc. by Medical Command (Department of the Army) on May 15, 2022.
How much is award W81XWH2210345 worth?
$936,000 has been obligated on W81XWH2210345.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award